Stock PODD INSULET CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Insulet Corporation

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
166.2 USD +1.23% Intraday chart for Insulet Corporation -0.04% -23.41%
Mar. 20 US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady MT
Mar. 20 Insulet Names Ana Maria Chadwick Finance Chief MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,584 16,853 18,350 20,445 15,151 11,637 - -
Enterprise Value (EV) 1 11,096 16,949 18,807 21,172 15,863 12,029 11,718 11,361
P/E ratio 901 x 2,556 x 1,109 x 4,206 x 73.8 x 56.4 x 44.1 x 33.7 x
Yield - - - - - - - -
Capitalization / Revenue 14.3 x 18.6 x 16.7 x 15.7 x 8.93 x 5.94 x 5.01 x 4.26 x
EV / Revenue 15 x 18.7 x 17.1 x 16.2 x 9.35 x 6.14 x 5.04 x 4.16 x
EV / EBITDA 142 x 139 x 103 x 94.2 x 48.2 x 30.2 x 23.9 x 18.9 x
EV / FCF -170 x -377 x -104 x -5,429 x 226 x 43.8 x 44.4 x 30.1 x
FCF Yield -0.59% -0.27% -0.96% -0.02% 0.44% 2.28% 2.25% 3.32%
Price to Book 141 x 28 x 33.1 x 43 x 21.8 x 11.1 x 8.19 x 6.11 x
Nbr of stocks (in thousands) 61,822 65,928 68,967 69,449 69,828 70,022 - -
Reference price 2 171.2 255.6 266.1 294.4 217.0 166.2 166.2 166.2
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 738.2 904.4 1,099 1,305 1,697 1,961 2,323 2,733
EBITDA 1 77.9 121.5 183.4 224.8 329.2 397.7 489.4 600.4
EBIT 1 50 66.1 126 124.1 208.5 254.8 335.8 443.4
Operating Margin 6.77% 7.31% 11.47% 9.51% 12.29% 13% 14.45% 16.22%
Earnings before Tax (EBT) 1 14.5 9.7 20.5 9.8 214.6 252.3 336.6 445.2
Net income 1 11.6 6.8 16.8 4.6 206.3 214.7 279.1 368.3
Net margin 1.57% 0.75% 1.53% 0.35% 12.16% 10.95% 12.01% 13.48%
EPS 2 0.1900 0.1000 0.2400 0.0700 2.940 2.945 3.768 4.930
Free Cash Flow 1 -65.3 -45 -180 -3.9 70.1 274.5 263.8 377.1
FCF margin -8.85% -4.98% -16.38% -0.3% 4.13% 14% 11.35% 13.8%
FCF Conversion (EBITDA) - - - - 21.29% 69.01% 53.9% 62.81%
FCF Conversion (Net income) - - - - 33.98% 127.82% 94.49% 102.39%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 275.6 307.7 295.4 299.4 340.8 369.7 358.1 396.5 432.7 509.8 425 456.4 506.6 570.9 523.1
EBITDA 1 55.7 64.6 63 27.6 62.8 71.4 48.8 61.3 82.8 137 79.76 80.6 102.6 135.3 137
EBIT 1 33.7 49.7 37.9 -26.7 2.9 42.5 19.7 30.3 52.9 105.5 32.46 47.07 71.55 103.9 56.58
Operating Margin 12.23% 16.15% 12.83% -8.92% 0.85% 11.5% 5.5% 7.64% 12.23% 20.69% 7.64% 10.31% 14.12% 18.2% 10.82%
Earnings before Tax (EBT) 1 15.2 33.4 29.3 -36.1 -5.7 22.3 24.6 28.5 53.7 107.8 37.22 52.13 69.52 96.21 57.48
Net income 1 12.6 29.2 27.8 -35 -5.2 17 23.8 27.3 51.9 103.3 30.35 42.51 59.37 81.97 48.43
Net margin 4.57% 9.49% 9.41% -11.69% -1.53% 4.6% 6.65% 6.89% 11.99% 20.26% 7.14% 9.31% 11.72% 14.36% 9.26%
EPS 2 0.1800 0.4200 0.4000 -0.5000 -0.0800 0.2400 0.3400 0.3900 0.7400 1.440 0.3974 0.5703 0.8272 1.140 0.6557
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/23/22 5/5/22 8/4/22 11/3/22 2/23/23 5/4/23 8/8/23 11/2/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 512 96.1 457 727 712 392 81.4 -
Net Cash position 1 - - - - - - - 276
Leverage (Debt/EBITDA) 6.57 x 0.7909 x 2.493 x 3.234 x 2.162 x 0.9859 x 0.1663 x -
Free Cash Flow 1 -65.3 -45 -180 -3.9 70.1 274 264 377
ROE (net income / shareholders' equity) 12.9% 5.01% 2.9% 17.6% 34.1% 24.7% 22.4% 21.4%
ROA (Net income/ Total Assets) 1.12% 1.13% 0.86% 4.24% 8.53% 9.23% 10.6% 10.6%
Assets 1 1,036 601.9 1,960 108.6 2,420 2,326 2,637 3,459
Book Value Per Share 2 1.210 9.140 8.040 6.850 9.950 15.00 20.30 27.20
Cash Flow per Share 2 1.580 1.270 -0.9900 1.700 1.980 5.280 4.450 4.780
Capex 1 164 129 112 123 75.6 169 132 128
Capex / Sales 22.18% 14.26% 10.18% 9.42% 4.45% 8.59% 5.7% 4.67%
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Insulet Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
166.2 USD
Average target price
236.3 USD
Spread / Average Target
+42.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
INSULET CORPORATION Stock Insulet Corporation
-23.41% 11.64B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. PODD Stock
  4. Financials Insulet Corporation